Silexion Therapeutics wins Nasdaq hearing to stay listed; transfer to Capital Market with equity conditions

Silexion Therapeutics Corp

Nasdaq panel granted continued listing subject to achieving $2.5M shareholders' equity by Sept 19, 2025.
Shares and warrants transfer from Global Market to Nasdaq Capital Market effective July 8, 2025, under same symbols.
To cure potential bid price deficiency, company plans 1-for-15 reverse share split after shareholder meeting on July 14, 2025.

item 8.01

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.